Medicine

Trastuzumab deruxtecan in HER2-positive state-of-the-art bosom cancer with or even without brain metastases: a phase 3b\/4 test

.Attributes Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of people along with HER2+ enhanced breast cancer cells and also active or even secure brain metastases showed regular intracranial task and also systemic effectiveness of T-DXd.